Author Question: Describe the conventional protocol for developing new psychotherapeutic drugs. Recommend one way in ... (Read 51 times)

dmcintosh

  • Hero Member
  • *****
  • Posts: 517
Describe the conventional protocol for developing new psychotherapeutic drugs. Recommend one way in which you think that this protocol could be improved. Discuss your recommendation.
 
  What will be an ideal response?

Question 2

Describe three animal models of anxiety. What is the problem with using them to screen potential anxiolytic drugs?
 
  What will be an ideal response?



billybob123

  • Sr. Member
  • ****
  • Posts: 336
Answer to Question 1

Answer:
75 for describing the phases of drug development
25 for making a reasonable recommendation for improving the standard protocol

Answer to Question 2

Answer:
75 for describing the three models
25 for explaining the problem in using them to screen anxiolytic drugs



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

There are over 65,000 known species of protozoa. About 10,000 species are parasitic.

Did you know?

Before a vaccine is licensed in the USA, the Food and Drug Administration (FDA) reviews it for safety and effectiveness. The CDC then reviews all studies again, as well as the American Academy of Pediatrics and the American Academy of Family Physicians. Every lot of vaccine is tested before administration to the public, and the FDA regularly inspects vaccine manufacturers' facilities.

Did you know?

The first war in which wide-scale use of anesthetics occurred was the Civil War, and 80% of all wounds were in the extremities.

Did you know?

Signs of depression include feeling sad most of the time for 2 weeks or longer; loss of interest in things normally enjoyed; lack of energy; sleep and appetite disturbances; weight changes; feelings of hopelessness, helplessness, or worthlessness; an inability to make decisions; and thoughts of death and suicide.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library